Trials / Recruiting
RecruitingNCT07266441
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 157 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-79635322 | JNJ-79635322 will be administered as an injection under the skin. |
Timeline
- Start date
- 2026-02-08
- Primary completion
- 2027-06-14
- Completion
- 2028-12-12
- First posted
- 2025-12-05
- Last updated
- 2026-04-13
Locations
31 sites across 3 countries: United States, Israel, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07266441. Inclusion in this directory is not an endorsement.